---
title: "MNKD.US (MNKD.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MNKD.US/news.md"
symbol: "MNKD.US"
name: "MNKD.US"
parent: "https://longbridge.com/en/quote/MNKD.US.md"
datetime: "2026-05-20T07:24:04.444Z"
locales:
  - [en](https://longbridge.com/en/quote/MNKD.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MNKD.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MNKD.US/news.md)
---

# MNKD.US (MNKD.US) — Related News

### [](https://longbridge.com/en/news/285572181.md)
*2026-05-07T14:33:18.000Z*
> The Nasdaq Biotechnology Index fell more than 1.9%. Among its constituents, Entrada Therapeutics dropped 55.80%, Phibro 

### [U.S. stock night trading volatility: Mannkind fell 7.87% in night trading, pressured by poor earnings report and market concerns](https://longbridge.com/en/news/285490554.md)
*2026-05-07T05:46:50.000Z*
> Mannkind fell 7.87% in the night session; BeiGene fell 0.37% in the night session, with a transaction volume of USD 1.49

### [](https://longbridge.com/en/news/285446480.md)
*2026-05-06T21:54:29.000Z*
> The Nasdaq Biotechnology Index rose more than 2.1%. Among its constituents, Pyxis Oncology surged 25.68%, Veracyte climb

### [Mannkind | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 90.17 M](https://longbridge.com/en/news/285429699.md)
*2026-05-06T20:11:24.000Z*
### [Mannkind | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 90.17 M](https://longbridge.com/en/news/285428390.md)
*2026-05-06T20:07:22.000Z*
### [MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged](https://longbridge.com/en/news/285419979.md)
*2026-05-06T18:15:35.000Z*
> Wedbush analyst Yun Zhong has reiterated a Buy rating for MannKind (MNKD) stock, maintaining an $8 price target. This de

### [12 Industrials Stocks Moving In Wednesday's Intraday Session](https://longbridge.com/en/news/285416085.md)
*2026-05-06T17:05:45.000Z*
> In Wednesday's trading session, BlueLinx Holdings (NYSE:BXC) saw a significant gain of 28.8%, reaching $59.5, following